Regeneron Pharmaceuticals Inc (REGN)

Total asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	14,185,900	13,812,700	13,436,900	13,029,000	13,044,200	13,025,200	12,601,200	12,306,100	12,113,500	13,654,100	14,171,800	16,451,800	16,014,400	13,499,700	12,328,800	9,147,000	8,455,000	8,201,600	7,974,500	7,957,900
Total assets	US$ in thousands	37,759,400	37,441,900	36,086,800	34,369,600	33,080,200	32,163,300	30,657,500	30,059,900	29,214,500	27,677,800	27,205,800	26,348,700	25,434,800	23,671,500	21,485,900	17,772,200	17,163,300	16,084,000	14,428,700	15,757,500
Total asset turnover		0.38	0.37	0.37	0.38	0.39	0.40	0.41	0.41	0.41	0.49	0.52	0.62	0.63	0.57	0.57	0.51	0.49	0.51	0.55	0.51

December 31, 2024 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $14,185,900K ÷ $37,759,400K
= 0.38

Regeneron Pharmaceuticals Inc's total asset turnover has fluctuated over the past few years, starting at 0.51 in March 2020, reaching a peak of 0.63 in December 2021, and then declining to 0.37 by December 2024. This ratio indicates the company's efficiency in generating revenues relative to its total assets. Generally, a higher total asset turnover signifies better asset utilization and operational efficiency.

The declining trend in total asset turnover from 2021 to 2024 may suggest potential issues in the company's operations, such as inefficient asset management or challenges in generating sufficient revenue from its asset base. Investors and stakeholders may further investigate the reasons behind this decline to assess the company's financial health and sustainability.